| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.2 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.08 | 0.2 |